{
  "ticker": "LDX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959567",
  "id": "02959567",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250618",
  "time": "0945",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvr7rlb1dmp0.pdf",
  "summary": "- **FebriDx CLIA Waiver Study Milestone Achieved**:  \n  - 500th patient enrolled, triggering **US$298,457 milestone payment** from BARDA.  \n  - **78 bacterial-positive patients** recruited (65% of 120-target). Current bacterial prevalence rate: **~35%** (post-enrichment strategy).  \n  - Next milestone: **US$746,143** upon \"Last Patient Enrolled.\"  \n\n- **Timeline & Market Opportunity**:  \n  - Study completion expected **Q4 CY2025**; FDA CLIA waiver application targeted for **October 2025**.  \n  - CLIA waiver could unlock **US$1.0 billion+ U.S. addressable market**.  \n\n- **Financial Impact**:  \n  - Total BARDA milestone payments received to date: **US$1,223,674** (of **US$2,984,571** total committed).  \n\n*No material capital markets or trading-specific actions (e.g., raising, halt) identified.*",
  "usage": {
    "prompt_tokens": 1448,
    "completion_tokens": 215,
    "total_tokens": 1663,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T23:54:59.463742"
}